The structural basis for agonist and partial agonist action on a β1-adrenergic receptor

被引:505
|
作者
Warne, Tony [1 ]
Moukhametzianov, Rouslan [1 ]
Baker, Jillian G. [2 ]
Nehme, Rony [1 ]
Edwards, Patricia C. [1 ]
Leslie, Andrew G. W. [1 ]
Schertler, Gebhard F. X. [1 ]
Tate, Christopher G. [1 ]
机构
[1] MRC, Mol Biol Lab, Cambridge CB2 0QH, England
[2] Univ Nottingham, Sch Med, Inst Cell Signalling, Queens Med Ctr, Nottingham NG7 2UH, England
基金
英国生物技术与生命科学研究理事会; 英国惠康基金;
关键词
PROTEIN-COUPLED RECEPTOR; BETA-ADRENERGIC-RECEPTORS; HIGH-AFFINITY BINDING; BETA(2)-ADRENERGIC RECEPTOR; CRYSTAL-STRUCTURE; LIGAND-BINDING; AMINO-ACID; ACTIVATION; CRYSTALLOGRAPHY; CRYSTALLIZATION;
D O I
10.1038/nature09746
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
beta-adrenergic receptors (beta ARs) are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins upon binding catecholamine agonist ligands such as adrenaline and noradrenaline(1,2). Synthetic ligands have been developed that either activate or inhibit beta ARs for the treatment of asthma, hypertension or cardiac dysfunction. These ligands are classified as either full agonists, partial agonists or antagonists, depending on whether the cellular response is similar to that of the native ligand, reduced or inhibited, respectively. However, the structural basis for these different ligand efficacies is unknown. Here we present four crystal structures of the thermo-stabilized turkey (Meleagris gallopavo) beta(1)-adrenergic receptor (beta(1)AR-m23) bound to the full agonists carmoterol and isoprenaline and the partial agonists salbutamol and dobutamine. In each case, agonist binding induces a 1 angstrom contraction of the catecholamine-binding pocket relative to the antagonist bound receptor. Full agonists can form hydrogen bonds with two conserved serine residues in transmembrane helix 5 (Ser(5.42) and Ser(5.46)), but partial agonists only interact with Ser(5.42) (superscripts refer to Ballesteros-Weinstein numbering(3)). The structures provide an understanding of the pharmacological differences between different ligand classes, illuminating how GPCRs function and providing a solid foundation for the structure-based design of novel ligands with predictable efficacies.
引用
收藏
页码:241 / 244
页数:4
相关论文
共 50 条
  • [31] Differential regulation of β1- and β2-adrenergic receptor proteins, and β1-adrenergic receptor protein and mRNA expression in response to β-agonist exposure in isolated human heart preparations
    Wichman, SE
    Minobe, WA
    Roden, RL
    Port, JD
    Asano, K
    Bristow, MR
    CIRCULATION, 1998, 98 (17) : 491 - 491
  • [32] Structural Basis of Partial Agonism at the β2-Adrenergic Receptor
    Shukla, Arun K.
    BIOCHEMISTRY, 2019, 58 (03) : 137 - 139
  • [33] Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist
    Isaikina, Polina
    Tsai, Ching-Ju
    Dietz, Nikolaus
    Pamula, Filip
    Guixa-Gonzalez, Ramon
    Branco, Camila
    Schertler, Gebhard F. X.
    Hartley, Oliver
    Stahlberg, Henning
    Maier, Timm
    Deupi, Xavier
    Stephan
    PROTEIN SCIENCE, 2021, 30 : 23 - 23
  • [34] Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor
    Jiang, Longying
    Xiao, Desheng
    Li, Yubin
    Dai, Shuyan
    Qu, Lingzhi
    Chen, Xiaojuan
    Guo, Ming
    Wei, Hudie
    Chen, Yongheng
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 534 : 1047 - 1052
  • [35] Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist
    Isaikina, Polina
    Tsai, Ching-Ju
    Dietz, Nikolaus
    Pamula, Filip
    Grahl, Anne
    Goldie, Kenneth N.
    Guixa-Gonzalez, Ramon
    Branco, Camila
    Paolini-Bertrand, Marianne
    Calo, Nicolas
    Cerini, Fabrice
    Schertler, Gebhard F. X.
    Hartley, Oliver
    Stahlberg, Henning
    Maier, Timm
    Deupi, Xavier
    Grzesiek, Stephan
    SCIENCE ADVANCES, 2021, 7 (25)
  • [36] Affinity and potency of P7480, a novel agonist, at rat and human α1-adrenergic receptor (AR) subtypes in vitro.
    Vargas, HM
    Cunningham, D
    Brooks, KM
    Gross, L
    Stepan, G
    Blue, DR
    FASEB JOURNAL, 1998, 12 (04): : A445 - A445
  • [37] Astrocyte β1-adrenergic receptor immunoreactivity and agonist induced increases in [Ca2+]i -: Differential results indicative of a modified membrane receptor
    Thorlin, T
    Persson, PAI
    Eriksson, PS
    Rönnbäck, L
    Hansson, E
    LIFE SCIENCES, 2000, 67 (11) : 1285 - 1296
  • [38] The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective κ-opioid receptor agonist, enadoline, in the monoamine-depleted rat
    Hill, MP
    Brotchie, JM
    BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (07) : 1577 - 1585
  • [39] Alternate synthesis of a β-3 adrenergic receptor agonist
    Scott, RW
    Fox, DE
    Wong, JW
    Burns, MP
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2004, 8 (04) : 587 - 592
  • [40] Structural Basis of the Bivalency of the TRPV1 Agonist DkTx
    Ramanujam, Venkatraman
    Crawford, Theo
    Cristofori-Armstrong, Ben
    Deuis, Jennifer R.
    Jia, Xinying
    Maxwell, Michael J.
    Jami, Sina
    Ma, Linlin
    Vetter, Irina
    Mobli, Mehdi
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2024, 63 (03)